Cancer is often characterized by dysregulation in cellular pathways and the checkpoints which control cell proliferation, growth, differentiation, and apoptosis. Within the genome there are two types of genes which carefully control cell proliferation and cell death, which are often the driving force behind oncogenesis.
9 result(s)
mTOR, the mechanistic target of rapamycin, sits at the center of a signaling network that coordinates cell growth based on environmental cues and plays an integral role in both cellular and organismal physiology.
Colorectal cancer (CRC) is the abnormal cell growth starting in the lining of the large intestine or rectum
The Toll-like receptors (TLRs) are a family of evolutionarily ancient Patten Recognition Receptors (PRRs) that rapidly detect microbial infection and stimulate the production of pro-inflammatory and antiviral cytokines and chemokines, as well as initiating significant metabolic shifts within the cell. Acting as cellular sentinels for infectious threats, signalling downstream of TLRs sets the stage for successful development of adaptive immunity 1.
Functional Genomic and Cell Panel Screening can individually provide comprehensive data sets to support therapeutic development, but when utilized in combination they identify novel targets which are cross-validated by independent approaches.
Cell panel screening assays are an essential part of the drug discovery toolbox. However, fully resolving the drug response profiles of slow-acting therapeutics remains challenging with conventional short term assay formats. Elucidation of the effects of these drug candidates, and those that target epigenetic pathways, requires much greater optimization of longer-term assay conditions.
The reasoning and research behind our Dharmacon™ CRISPRi platform recently published in The CRISPR Journal.
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.
Choosing the right cell-based screen from the plethora of options available can quickly become a complicated decision process. Here, we review two of the major options: cell panel and functional genomic screening.